High blood pressure care: Beyond the clinical setting;Más allá del ámbito clínico en el cuidado de la hipertensión arterial

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 28, Issue 4, 2010, Pages 311-318

  Ordúñez García, Pedro ^a   Pérez Flores, Enrique ^a   Hospedales, James ^a  

^a Organizacion Panamericana de la Salud   (Mexico)

Author keywords

Cardiovascular diseases; Chronic disease; Health services; Hypertension

Indexed keywords

BLOOD SYSTEM DISORDER; CARDIOVASCULAR DISEASE; DISEASE TREATMENT; EPIDEMIOLOGY; ETIOLOGY; HEALTH CARE; HEALTH SERVICES; HYPERTENSION; INTEGRATED APPROACH; PUBLIC HEALTH;

ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; PUBLIC HEALTH;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PUBLIC HEALTH;

EID: 78650665990     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Emberson JR, Whincup PH, Morris RW, Walker M. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J. 2003;24:1719-26.
2. World Health Organization (WHO). The world health report 2002. Reducing Risks, Promoting Healthy Life. WHO: Geneva; 2002. Hallado en: http://www. who.int/whr/2002/en/. Acceso el 20 de agosto de 2010.
3. Brookes L. Guidelines -JNC 8- To Be Announced? Medscape Cardiology. 2008. Hallado en: http://www.med scape.com/viewarticle/585305. Acceso el 15 octubre de 2010.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2460-72.
5. [Erratum: JAMA. 2003;290:197]
6. Chobanian AV. The Hypertension Paradox- More Uncontrolled Disease despite Improved Therapy. N Engl J Med. 2009;361:878-87.
7. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-10. (Pubitemid 34252058)
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
9. [Erratum: Lancet. 2003;361:1060.]
10. Chobanian AV. Prehypertension revisited. Hypertension. 2006;48 812-4
11. Toprak A, Wang H, Chen W, Paul T, Ruan L, Srinivasan S, et al. Prehypertension and black-white contrasts in cardiovascular risk in young adults: Bogalusa Heart Study. J Hypertens. 2009;27:243-50.
12. Mancia G, De Backer G, Dominczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 24:1104-87.
13. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ. 2003;326:1427-34.
14. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
15. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004; 17:793-801.
16. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al for the Accomplish Trial Investigators. Benazepril plus amlodipine of hydrochlorothiazide for hypertension in high-risk. N Engl J Med. 2008;349:2417-28.
17. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.
18. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27: 1047-53.
19. Orduñez P, Barceló A, Bernal JL, Espinosa A, Silva LC, Cooper RS. Risk factors associated with uncontrolled hypertension: findings from the baseline CARMEN survey in Cienfuegos, Cuba. J Hypertens. 2008;26:663-71
20. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-86.
21. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the healthy people: 2010 blood pressure control goals. Hypertension. 2006;47:345-51.
22. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-53.
23. World Health Organization (WHO). Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: WHO; 2007. Hallado en: http://www.who.int/cardiovascular-diseases/guid elines/Full%20text.pdf. Acceso el 21 de agosto de 2010.
24. Orduñez P, Munoz JLB, Pedraza D, Silva LC, Espinoza-Brito A, Cooper RS. Success in control of hypertension in a low-resource setting: the Cuban experience. J Hypertens. 2006;24:845-9.
25. McKeown T. The Role of Medicine: Dream, Mirage, or Nemesis? London, England: Nuffield Provincial Hospitals Trust; 1976.
26. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006; 355:920-7.
27. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000. N Engl J Med. 2007;356:2388-98.
28. Wagner EH, Glasgow RE, Davis C, Bonomi AE, Provost L, McCulloch D, et al. Quality Improvement in Chronic Illness Care: A Collaborative Approach. Jt Comm J Qual Improv. 2001;27(2):63-80.
29. Pan American Health Organization (PAHO). Integrated Delivery Networks. Concepts, Policy Options, and Road Map for Implementation in the Americas. (Series: Renewing Primary Health Care in the Americas). Washington, D.C.: PAHO; 2008.
30. Pan American Health Organization (PAHO). Renewing Primary Health Care in the Americas: A Position Paper of the Pan American Health Organization/ World Health Organization. Washington, D.C.: PAHO; 2007.
31. Organización Panamericana de la Salud (OPS). La formación en medicina orientada hacia la atención primaria de salud. (Serie La renovación de la atención primaria de salud en las Américas. No. 2). Washington D.C: OPS; 2008.
32. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and re- gional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-57.
33. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ, Comparative Risk Assessment Group. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet. 2003;362: 271-80.
34. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360: 1903-13.
35. MacMahon S. Blood pressure and the prevention of stroke. J Hypertens Suppl. 1996;14(6):S39-46.
36. Briefel RR, Johnson CL. Secular trends in dietary intake in the United States. Annu Rev Nutr. 2004;24:401-31.
37. Cohen HW, Hailpern SM, Fang J, Alderman MH. Sodium intake and mortality in the NHANES II follow-up study. Am J Med. 2006;119(3):275.e7-14.
38. Dahl LK, Love RA. Evidence for relationship between sodium (chloride) intake and human essential hypertension. Arch Intern Med. 1954;94:525-31.
39. Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356:1966-78.
40. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Human Hypertens. 2009;23:363-84.
41. Sasaki N. The salt factor in apoplexy and hypertension: epidemiological studies in Japan. In: Yamori Y, ed. Prophylactic Approach to Hypertensive Diseases. New York: Raven Press; 1979. Pp. 467-74
42. Karppanen H, Mervaala E. Sodium intake and hypertension. Prog Cardiovasc Dis. 2006;49:59-75.
43. He FJ, MacGregor GA. How far should salt intake be reduced? Hypertension. 2003;42:1093-9.
44. Institute of Medicine of the National Academies. Panel on Dietary Reference Intakes for Electrolytes and Water, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes for water, potassium, sodium chloride, and sulfate. Washington, DC: National Academies Press; 2004. Hallado en: http://www.nap.edu/open book.php?isbn= 0309091691. Acceso el 21 de agosto de 2010.
45. World Health Organization (WHO). Reducing salt intake in populations: report of a WHO forum and technical meeting, 4-7 October 2006 Paris, France. Geneva: WHO; 2007.
46. PAHO Experts Recommend Lowering Salt Consumption to Save Lives. Reducing dietary salt consumption is a top priority in chronic disease prevention. Hallado en: http://new.paho.org/hq/index.php?option=com-content&task= view&id=1769&Itemid=1. Acceso el 21 de agosto de 2010.
47. Centers for Disease Control and Prevention. Recommended Community Strategies and Measurements to Prevent Obesity in the United States. MMWR Recomm Rep. 2009;58(RR-07):1-26.
48. Trust for America's Health, Robert Wood Johnson Foundation. F as in fat: how obesity policies are failing in America. Princeton, NJ: Robert Wood Johnson Foundation; 2008. Hallado en: http://www.healthyeatingresearch.org/images/ stories/her-externalreports/obesity2008report.pdf. Acceso el 21 de agosto de 2010.
49. Braveman P. A health disparities perspective on obesity research. Prev Chronic Dis. 2009;6(3):A91.
50. Gordon-Larsen P, Nelson MC, Page P, Popkin BM. Inequality in the built environment underlies key health disparities in physical activity and obesity. Pediatrics. 2006;117(2):417-24.
51. Morland K, Diez Roux AV, Wing S. Supermarkets, other food stores, and obesity: the Atherosclerosis Risk in Communities Study. Am J Prev Med. 2006; 30(4):333-9.
52. Hammond RA. Complex systems modeling for obesity research. Prev Chronic Dis. 2009;6(3):A97.
53. Centers for Disease Control and Prevention. Recommended Community Strategies and Measurements to Prevent Obesity in the United States. MMWR Recomm Rep. 2009;58(RR-07):1-26.
54. Cooper RS. Using Public Health Indicators to Measure the Success of Hypertension Control. Hypertension. 2007;49 (4):773-4.
55. Pan American Health Organization (PAHO). Regional strategy and plan of action on an integrated approach to the prevention and control of chronic diseases. Washington, D.C: PAHO, 2007.
56. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, et al. Prevention of cardiovascular disease in highrisk individuals in low-income and middle- income countries: health effects and costs. Lancet. 2007;370:2054-62.
57. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol. 2002;31:285-93.
58. World Health Organization (WHO). Closing the gap in a generation: health equity through action on the social determinants of health. Final Report of the Commission on Social Determinants of Health. Geneva: WHO; 2008.